Molecular Profiling of Bladder Cancer

Urothelial bladder cancer is the most common type of urinary tract cancer. In the United States, 81,190 cases and 17,240 deaths were estimated for 2018 (ACS 2018).

Most bladder cancer is uroepithelial; less common subtypes are squamous cell and adenocarcinoma (NCI 2012). Early stages of bladder cancer are treated with surgery, radiation, or a combination of treatments including chemotherapy (NCI 2012). Tumor resection often leads to cure in early stage patients. Intravesical chemotherapy is also sometimes used. For patients with more advanced tumors, removal of the bladder is the most common treatment. Surgery may be followed by radiation or chemotherapy.

While targeted therapies are being investigated for use in advanced bladder cancer, progress has been slow. Promising targets for therapy include EGFR, FGFR3, mTOR, PIK3CA, RAS, and VEGF (Iyer et al. 2012; Saghedi and Garcia 2012; Sjodahl et al. 2011; Williams, Hurst, and Knowles 2012​).

​​

Contributors: David Solit, M.D.

Suggested Citation: Solit, D. 2018. Molecular Profiling of Bladder Cancer. My Cancer Genome https://www.padiracinnovation.org/content/disease/bladder-cancer/ (Updated March 16).

Last Updated: March 16, 2018

Disclaimer: The information presented at padiracinnovation.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.